middle.news
Avecho Nears Breakthrough with Interim Results in Phase III CBD Insomnia Trial
9:32am on Monday 2nd of March, 2026 AEDT
•
Healthcare
Read Story
Avecho Nears Breakthrough with Interim Results in Phase III CBD Insomnia Trial
9:32am on Monday 2nd of March, 2026 AEDT
Key Points
Completed recruitment of ~210 patients for interim analysis cohort
Interim analysis results anticipated in June 2026
Commercial partnership secured with Sandoz AG for Australian market
Targeting TGA approval for over-the-counter CBD insomnia treatment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Avecho Biotechnology (ASX:AVE)
OPEN ARTICLE